Direct oral anticoagulants, warfarin appear equally safe in morbidly obese patients

NEW YORK (Reuters Health) - 13/6/2019

Direct oral anticoagulants and warfarin appear to be similarly safe in morbidly obese patients with atrial fibrillation (AF) and venous thromboembolism (VTE), according to new findings.

Long-standing AF tied to outcomes of left-atrial-appendage occlusion

NEW YORK (Reuters Health) - 6/6/2019

Long-standing persistent atrial fibrillation (LSPAF) is associated with more residual leak following percutaneous left atrial appendage (LAA) occlusion with the Watchman device, according to one of two new studies of LAA closure.

New-onset atrial fibrillation common after aortic-valve replacement

NEW YORK (Reuters Health) - 4/6/2019

About half of inpatients who undergo transcatheter aortic-valve implantation (TAVI) or surgical aortic-valve replacement (AVR) develop new-onset atrial fibrillation (AF), according to data from the National Inpatient Sample (NIS).

Worse outcomes seen in AF patients with ischemic cardiomyopathy

NEW YORK (Reuters Health) - 23/5/2019

Patients with atrial fibrillation (AF) and ischemic cardiomyopathy have higher one-year mortality rates than similar patients with nonischemic cardiomyopathy, according to results from the GARFIELD-AF registry.


Peritoneal carcinomatosis profiles highlight gastric cancer targets

NEW YORK (Reuters Health) - 20/6/2019

Sequencing of whole exome and transcriptome of peritoneal carcinomatosis (PC) in patients with gastric adenocarcinoma (GAC) has given novel insights and opened up new therapeutic opportunities, according to Texas-based researchers.

Anti-TNF therapy for IBD can be safely stopped before third trimester

NEW YORK (Reuters Health) - 19/6/2019

Anti-tumor necrosis factor (TNF) therapy in pregnant women with inflammatory bowel disease (IBD) can be discontinued before week 30 of gestation without increasing relapse risk or harming the fetus, researchers report.

Low-FODMAP diet has little effect on micronutrients intake in short term

NEW YORK (Reuters Health) - 18/6/2019

Following a low-FODMAP diet for a limited period appears not to reduce the mean daily intake of most micronutrients in adults with irritable bowel syndrome (IBS) with diarrhea, a new study suggests.

No reductions in IBD hospitalizations, surgeries after infliximab approval in Canada

NEW YORK (Reuters Health) - 17/6/2019

Introduction of infliximab, the first biologic therapy approved for inflammatory bowel disease (IBD) in Canada, did not lead to lower rates of hospitalizations or intestinal surgeries for the disorder in Ontario, researchers say.

Half of severely obese GERD patients still have reflux after surgery

NEW YORK (Reuters Health) - 14/6/2019

Gastric-bypass surgery leads to rapid improvement in reflux symptoms in obese patients with gastroesophageal reflux (GERD), but about half still need anti-reflux medication afterwards, new research shows.

Colorectal-tumor screening for Lynch syndrome has low yield in elderly

NEW YORK (Reuters Health) - 12/6/2019

The diagnostic yield of universal screening of colorectal tumors for Lynch syndrome decreases substantially after ages 70 to 75, a retrospective study suggests.

Inflammatory bowel disease patients have higher health costs

(Reuters Health) - 7/6/2019

People with inflammatory bowel disease (IBD) - either Crohn's disease or ulcerative colitis - may incur health costs more than three times higher than individuals without these conditions, a U.S. study suggests.

Laparoscopic on par with open surgery for colorectal-cancer liver metastases

NEW YORK (Reuters Health) - 5/6/2019

Laparoscopic surgery is just as effective long-term as open surgery for patients undergoing removal of colorectal cancer that has spread to the liver, according to results of the OSLO-COMET study.

Vedolizumab likely unhelpful for extra-intestinal manifestations of IBD

NEW YORK (Reuters Health) - 3/6/2019

There is "no strong evidence" to suggest that vedolizumab can treat pre-existing extra-intestinal manifestations (EIMs) of inflammatory bowel disease (IBD), although the drug may reduce the occurrence of new ones, a systematic review suggests.

Fixed-dose enoxaparin prophylaxis often inadequate for colorectal surgery

NEW YORK (Reuters Health) - 30/5/2019

Most patients undergoing colorectal surgery don't get adequate anticoagulation from the FDA-approved 40 mg daily dose of enoxaparin, possibly setting the stage for breakthrough venous thromboembolism, researchers say.

IBS patients found to have atypical food allergies

NEW YORK (Reuters Health) - 29/5/2019

A confocal laser endomicroscopy (CLE) analysis of patients with irritable bowel syndrome (IBS) revealed that more than half may have atypical, IgE-negative food allergies.

Early endoscopic remission linked to altered course of Crohn's disease

NEW YORK (Reuters Health) - 29/5/2019

Patients with early Crohn's disease who achieve endoscopic or deep remission after one year of intensive treatment are less likely to experience disease progression over the next several years, new research shows.

Laparoscopic gastrectomy effective for locally advanced gastric cancer

NEW YORK (Reuters Health) - 29/5/2019

Laparoscopic gastrectomy is noninferior to open distal gastrectomy in patients with locally advanced gastric cancer, researchers from China report.

Perioperative FLOT chemotherapy improves survival with gastric cancer

NEW YORK (Reuters Health) - 27/5/2019

Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improves survival in patients with locally advanced resectable gastric adenocarcinoma, according to results from the FLOT4-AIO trial.

Machine-learning models help predict remission in Crohn's

NEW YORK (Reuters Health) - 23/5/2019

Machine learning models can help identify patients with Crohn's disease likely to be durable responders to ustekinumab before committing to long-term treatment, researchers report.

Overall diet quality in many with IBS is poor

NEW YORK (Reuters Health) - 23/5/2019

Many people with irritable bowel syndrome (IBS) don't get the nutrition they need, according to new research from the United Kingdom.

Hypoalbuminemia linked to worse outcomes after IBD surgery

NEW YORK (Reuters Health) - 15/5/2019

Hypoalbuminemia is associated with worse mortality and complication rates after major abdominal surgery related to inflammatory bowel disease (IBD), according to a database study.

Endoscopic sleeve gastroplasty linked to lasting weight loss without surgery

NEW YORK (Reuters Health) - 15/5/2019

Endoscopic sleeve gastroplasty was associated with significant weight loss in the first long-term study to follow patients over five years, report researchers from NewYork-Presbyterian/Weill Cornell Medical Center.

Novel test predicts IBD course at diagnosis

NEW YORK (Reuters Health) - 13/5/2019

A 17-gene classifier can predict the course of inflammatory bowel disease (IBD) at diagnosis, helping to set the stage for personalized therapy, researchers in the UK say.

Breath analysis shows promise in distinguishing IBD types

NEW YORK (Reuters Health) - 9/5/2019

A breath analyzer can identify inflammatory bowel disease (IBD) in affected individuals and distinguish ulcerative colitis (UC) from Crohn's disease (CD), a pilot study reveals.

IBD transition coordinator may help adolescents switch to adult care

NEW YORK (Reuters Health) - 6/5/2019

A one-time intervention by an inflammatory bowel disease (IBD) transition coordinator appears to improve adolescent patients' self-management skills and readiness to transition to adult care, according to a retrospective chart review.

Laparoscopic surgery effective for chronic reflux-linked cough

NEW YORK (Reuters Health) - 3/5/2019

Laparoscopic antireflux surgery (LARS) is an effective treatment for chronic cough associated with gastroesophageal reflux disease, with three-quarters of patients having complete resolution of symptoms, researchers report.

Immunosuppressants found safe for IBD patients with cancer history

NEW YORK (Reuters Health) - 30/4/2019

Immunosuppressant therapies (IMTs) do not appear to increase the risk of new or recurrent cancers in inflammatory bowel disease (IBD) patients with a history of cancer unrelated to immunosuppression, new findings show.

Ustekinumab beneficial in refractory Crohn's disease in real world

NEW YORK (Reuters Health) - 30/4/2019

A real-world observational study confirms the benefit of ustekinumab in patients with Crohn's disease (CD) previously exposed to other biologics, according to Belgian researchers.

Bismuth quadruple therapy best for H. pylori eradication

NEW YORK (Reuters Health) - 26/4/2019

In settings where susceptibility data are hard to come by, 14 days of bismuth quadruple therapy is likely best for Helicobacter pylori eradication, researchers report.

Primary anastomosis with diverting loop ileostomy for acute diverticulitis found safe

NEW YORK (Reuters Health) - 24/4/2019

Primary anastomosis with diverting loop ileostomy (PADLI) is a safe alternative to Hartmann's procedure (HP) for emergency management of patients with acute diverticulitis, researchers report.

Gene signature linked to survival after pancreatic-cancer surgery

NEW YORK (Reuters Health) - 23/4/2019

In patients with pancreatic ductal adenocarcinoma (PDAC) presence of two single-nucleotide polymorphisms (SNPs) may help predict surgical outcome, according to European researchers.

MR enterography best identifies fibrotic vs inflammatory strictures in Crohn's disease

NEW YORK (Reuters Health) - 23/4/2019

Conventional imaging techniques accurately detect strictures in patients with Crohn's disease, but magnetic resonance enterography (MRE) best differentiates fibrotic from inflammatory components, researchers say.

IBD patients who switch from infliximab to biosimilar see mixed results

NEW YORK (Reuters Health) - 23/4/2019

Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report.

Therapy by phone or web improves patient-reported outcomes in IBS

NEW YORK (Reuters Health) - 23/4/2019

Cognitive behavioral therapy (CBT) delivered by phone or online leads to improvements in patient-reported outcomes in irritable bowel syndrome (IBS), according to a clinical trial from the U.K.

Certain factors predict celiac disease risk in children with positive serology but negative biopsy

NEW YORK (Reuters Health) - 23/4/2019

In children with "potential" celiac disease - positive serology but negative biopsy - who are not on gluten-free diets, factors that may help predict risk for eventual villous atrophy include age at diagnosis, gamma delta lymphocytes and HLA haplotype, researchers say.

IBD survey accurately captures patient-reported symptoms

NEW YORK (Reuters Health) - 12/4/2019

The Inflammatory Bowel Disease (IBD) Symptom Inventory accurately captures patient-reported symptoms and can be used to monitor patients in clinic or research settings, researchers from Canada report.

Esophageal reflux common after sleeve gastrectomy

NEW YORK (Reuters Health) - 12/4/2019

About one in four patients will develop gastroesophageal reflux disease (GERD) after sleeve gastrectomy, but few will require conversion to gastric bypass for severe reflux, according to a systematic review and meta-analysis.

Endoscopic surveillance finds unsuspected carcinomas in predisposed individuals

NEW YORK (Reuters Health) - 10/4/2019

Endoscopic surveillance can identify unsuspected signet-ring-cell carcinoma in individuals predisposed to hereditary diffuse gastric cancer (HDGC) by virtue of pathogenic variants in CDH1, researchers report.

Infliximab biosimilar CT-P13 noninferior in active Crohn's disease

NEW YORK (Reuters Health) - 9/4/2019

The infliximab biosimilar CT-P13 is noninferior to infliximab for treating patients with active Crohn's disease, according to a randomized controlled trial.

Colorectal cancer screening beginning at age 45 years could be cost-effective

NEW YORK (Reuters Health) - 5/4/2019

Colorectal cancer (CRC) screening beginning at age 45 years instead of 50 years for average-risk individuals is likely cost-effective, researchers report.

Endoscopic clip closure after large polyp resection in right colon reduces bleeding

NEW YORK (Reuters Health) - 3/4/2019

Endoscopic clip closure after resection of large sessile polyps in the proximal colon reduced the risk of post-procedure bleeding in a multicenter randomized trial, researchers say.

New monitoring system reduces blind spots during esophagogastroduodenoscopy

NEW YORK (Reuters Health) - 1/4/2019

The new WISENSE monitoring system reduces blind-spot rates during esophagogastroduodenoscopy (EGD), researchers from China report.

Glepaglutide treatment promising in short-bowel syndrome

NEW YORK (Reuters Health) - 29/3/2019

The novel long-acting glucagon-like peptide-2 analogue glepaglutide appears to improve intestinal function in patients with short-bowel syndrome, according to a small randomized trial.

Similar participation rates with 2 brands of fecal immunochemical test

NEW YORK (Reuters Health) - 28/3/2019

Two brands of fecal immunochemical tests (FITs), FOB-Gold and OC-Sensor, are associated with similar colorectal cancer (CRC) screening participation despite small differences in ease of use, Dutch researchers report.

Reduced-dose combo treatment helps some with metastatic colorectal cancer

NEW YORK (Reuters Health) - 26/3/2019

Reduced-dose combination chemotherapy improves progression-free survival, compared with full-dose monotherapy, in older vulnerable patients with metastatic colorectal cancer (CRC), according to results from the phase II NORDIC9 trial.

Partial fundoplication may have edge in treating GERD

NEW YORK (Reuters Health) - 15/3/2019

In surgical treatment of gastroesophageal reflux disease (GERD), partial fundoplication (PF) prompts less dysphagia than total fundoplication (TF), according to randomized trial results reported by Scandinavian researchers.

Optical technologies unreliable at diagnosing pre-cancerous colorectal polyps

NEW YORK (Reuters Health) - 14/3/2019

The accuracy of optical technologies in differentiating cancerous from benign tissue is "insufficient" for most routine clinical applications, including diagnosing pre-cancerous colorectal polyps, researchers say.

Early-onset colorectal cancer has distinct clinical and genetic features

NEW YORK (Reuters Health) - 13/3/2019

Colorectal cancer that is diagnosed before age 50 has clinical and genetic features that differ from those seen in colorectal cancer diagnosed later in life, according to new research.

T cell clonal expansion linked to postop recurrence of Crohn's in smokers

NEW YORK (Reuters Health) - 11/3/2019

Among smokers with Crohn's disease, increased T cell clonal expansion, especially in the CD8 compartment, is exaggerated and is associated with an increased rate of disease recurrence after ileocolonic resection, according to results from the REMIND Study Group.

Extended lymph node dissection safe in gastroesophageal carcinoma

NEW YORK (Reuters Health) - 8/3/2019

Extended lymphadenectomy (LAD) to improve staging accuracy for gastroesophageal carcinoma (GEC) can be done safely, according to a new case series.

Misdiagnosis of young-onset colorectal cancer common

NEW YORK (Reuters Health) - 7/3/2019

Many patients younger than age 50 who develop colorectal cancer are initially misdiagnosed, leading to a more advanced stage of disease when it is detected, according to a new study.

New risk score helps predict intra-abdominal abscess in Crohn's disease

NEW YORK (Reuters Health) - 5/3/2019

A new, five-parameter risk score accurately predicts intra-abdominal abscess in Crohn's disease (CD) patients presenting to the emergency department (ED), researchers from Israel report.

Beta-cell sensitivity reduced after gastric bypass surgery

NEW YORK (Reuters Health) - 4/3/2019

After gastric bypass surgery, beta-cells in nondiabetic patients are less sensitive to insulinotropic gut hormones, researchers report.

Model finds bariatric surgery cost-effective in NASH

NEW YORK (Reuters Health) - 1/3/2019

Bariatric surgery could extend life expectancy and quality-adjusted life-years (QALY) cost-effectively in overweight and obese patients with nonalcoholic steatohepatitis (NASH), a new modeling study suggests.

Sleeve gastrectomy may be safer than gastric bypass for IBD patients

NEW YORK (Reuters Health) - 28/2/2019

Most obese patients with inflammatory bowel disease (IBD) fare well after bariatric surgery, but gastric bypass could make Crohn's disease harder to control, new research suggests.

Fecal immunochemical tests useful for colorectal-cancer screening

NEW YORK (Reuters Health) - 26/2/2019

One-time fecal immunochemical tests (FIT) can be useful for identifying colorectal cancer (CRC), but they lack sensitivity for advanced adenomatous polyps, according to a systematic review and meta-analysis.

Routine diversion after sphincter-sparing rectal surgery tied to poorer outcomes

NEW YORK (Reuters Health) - 22/2/2019

Routine diversion after sphincter-sparing rectal cancer resection does not reduce anastomotic leaks and is associated with more reinterventions, readmissions, and higher costs, according to a database study.

Weight-loss surgery can bring lasting improvement in sexual function

(Reuters Health) - 22/2/2019

Weight-loss surgery has more benefits than simply slimming a patient down, it may also result in lasting improvements to sexual functioning, a new study suggests.

High-fat diet adversely affects gut microbiota

By Will Boggs MD - 22/2/2019

Higher-fat diets have unfavorable effects on gut microbiota, fecal metabolites and plasma proinflammatory factors, researchers from China report.

Laparoscopic gastrectomy outcome comparable to open surgery

NEW YORK (Reuters Health) - 13/2/2019

Patients with stage I gastric cancer who undergo laparoscopic distal gastrectomy have long-term-survival rates similar to those who have open distal gastrectomy, according to a clinical trial from South Korea.

Treg cells show promise as immunotherapy for Crohn's disease

NEW YORK (Reuters Health) - 13/2/2019

Crohn's disease (CD) symptoms may be reduced if an agonist of the retinoic acid receptor alpha (RARA) can be used to traffic T-regulatory (Treg) cells to inflamed intestinal tissues, researchers suggest.

Heavier red meat consumption tied to higher NAFLD risk

(Reuters Health) - 13/2/2019

People who eat a lot of animal protein may be more likely to have excessive fat in their livers and a higher risk of non-alcoholic fatty liver disease (NAFLD) than individuals whose main source of protein is vegetables, a Dutch study suggests.

GLP-1 enhances insulin secretion after bariatric surgery

NEW YORK (Reuters Health) - 12/2/2019

Glucagon-like peptide 1 (GLP-1) plays a major role in driving enhanced insulin secretion following bariatric surgery, researchers from the U.K. report.

Surgery may curb risk of recurrent adhesive small-bowel obstruction

NEW YORK (Reuters Health) - 8/2/2019

Surgical intervention reduces the risk that adhesive small-bowel obstruction (aSBO) will recur, whether it's done at the index episode or during recurrent episodes, researchers say.

Aspirin, anticoagulants up rate of false positives with FIT for colorectal cancer

NEW YORK (Reuters Health) - 7/2/2019

Regular use of aspirin or anticoagulants reduces the positive predictive value (PPV) of fecal immunochemical testing (FIT) for detecting colorectal cancer and advanced adenomas, researchers from Norway report.

Collagen signature helps predict lymph-node metastasis in gastric cancer

NEW YORK (Reuters Health) - 7/2/2019

In patients with early gastric cancer the collagen signature in the tumor microenvironment is an independent indicator of lymph-node metastasis, according to Chinese researchers.

Recurrence risk constant after ablation in Barrett's esophagus

NEW YORK (Reuters Health) - 5/2/2019

Diligent surveillance remains important after remission of intestinal metaplasia (CRIM) following radiofrequency ablation (RFA) in Barrett's esophagus, researchers say.

Multiple infliximab doses better for acute severe ulcerative colitis

NEW YORK (Reuters Health) - 1/2/2019

As salvage therapy for acute severe ulcerative colitis refractory to corticosteroids, multiple infliximab doses are superior to a single dose for improving colectomy-free survival, according to a new systematic review and meta-analysis.

Glycemic control tied to better outcome of anti-VEGF therapy for diabetic macular edema

NEW YORK (Reuters Health) - 1/2/2019

Strong glycemic control may optimize vision outcomes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (anti-VEGF) therapy, researchers say.

Azathioprine ups pancreatitis risk in pediatric IBD

NEW YORK (Reuters Health) - 31/1/2019

Azathioprine is associated with a six-fold increased risk of acute pancreatitis in children with inflammatory bowel disease (IBD), new research shows.

Adding vedolizumab to steroids may boost response, remission in Crohn's disease

NEW YORK (Reuters Health) - 30/1/2019

In patients with moderate to severe Crohn's disease who've been taking stable doses of steroids, adding vedolizumab may help induce a clinical response or remission, researchers say.

Postpartum substance abuse, mood disorders more common with IBD

NEW YORK (Reuters Health) - 25/1/2019

Inflammatory bowel disease (IBD), and Crohn's disease in particular, is associated with an increased risk of postpartum mood disorders and substance abuse, new findings in the journal Gut show.

Soluble fiber may improve diabetes control

(Reuters Health) - 24/1/2019

People with diabetes who take soluble fiber supplements have slightly lower blood sugar than their peers who don't add this type of fiber to their diets, a research review finds.

Younger, more insulin-sensitive T2DM patients benefit most from intensive insulin

NEW YORK (Reuters Health) - 23/1/2019

Patients with newly diagnosed type 2 diabetes can experience long-term glycemic remission with intensive insulin treatment - but this effect is more likely in younger patients and those with lower post-treatment glucose levels, according to new findings in the Journal of Clinical Endocrinology and Metabolism.

NAFLD in adolescent boys improves with low sugar diet

NEW YORK (Reuters Health) - 22/1/2019

Adolescent boys on a "low free sugar" diet show significant improvements in nonalcoholic fatty liver disease (NAFLD), according to results from an 8-week randomized clinical trial.

Hyperglycemia tied to higher fracture risk in elderly Japanese men

NEW YORK (Reuters Health) - 17/1/2019

Community-dwelling elderly men with hyperglycemia are at elevated risk of osteoporotic fracture, according to Japanese researchers.

Fecal-microbiota transplant boosts ulcerative colitis remission

NEW YORK (Reuters Health) - 16/1/2019

Anaerobically prepared fecal-microbiota transplantation (FMT) improved remission rates in adults with mild to moderate ulcerative colitis (UC) in a randomized trial.

Fecal-microbiota transplant beats antibiotics for recurrent C diff

NEW YORK (Reuters Health) - 16/1/2019

Fecal-microbiota transplantation (FMT) is superior to 10 days of fidaxomicin or vancomycin for resolving recurrent Clostridium difficile infection (CDI), according to results from a randomized open-label clinical trial.

Complications fewer, survival unaffected by less-invasive esophageal cancer surgery

(Reuters Health) - 9/1/2019

In patients with esophageal cancer, laparoscopic abdominal surgery combined with an open thoracotomy - i.e., hybrid minimally invasive esophagectomy - produces 77% fewer major complications than open esophagectomy without lowering survival, according to a study of more than 200 French patients reported January 9 online in The New England Journal of Medicine.

Serology an increasingly important indicator of celiac disease

NEW YORK (Reuters Health) - 9/1/2019

Serology has gained importance in the diagnosis of celiac disease (CD), due to improvements in assay performance over the last decade, according to updated advice for clinical practice.

Advanced endoscopic techniques improve IBD assessment

NEW YORK (Reuters Health) - 8/1/2019

Advanced endoscopic techniques allow for better assessment of mucosal healing and dysplasia in patients with inflammatory bowel disease (IBD), according to a new review.

Need for bariatric revision varies by primary operation

NEW YORK (Reuters Health) - 2/1/2019

Bariatric reoperations are more common after banding and vertical banded gastroplasty (VBG) than after gastric bypass (GBP), according to long-term follow-up of participants in the Swedish Obese Subjects (SOS) study.

Infectious diseases

London HIV patient becomes world's second AIDS cure hope

LONDON (Reuters) - 5/3/2019

An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Measles vaccine not linked with autism in high-risk kids

(Reuters Health) - 5/3/2019

The measles, mumps and rubella (MMR) vaccine isn't associated with an increased risk of autism even among kids who are at high risk because they have a sibling with the disorder, a Danish study suggests.

Stopping oral antiviral therapy in chronic hep B possible for some people

NEW YORK (Reuters Health) - 4/3/2019

A new analysis provides insight into what happens after stopping tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients with persistent viral suppression who took the drug for at least eight years.

Low rates of viral suppression among young black men with HIV

NEW YORK (Reuters Health) - 1/3/2019

Young black men with HIV have far lower rates of viral suppression than others with HIV, according to results from the Medical Monitoring Project (MMP).


Targeted therapies linked to survival benefits for older patients with advanced renal cancer

NEW YORK (Reuters Health) - 21/6/2019

Targeted therapies were associated with "modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.

Niraparib-pembrolizumab combo may have benefit in ovarian, breast cancers

NEW YORK (Reuters Health) - 20/6/2019

Niraparib in combination with pembrolizumab may show promise in women with recurrent platinum-resistant ovarian carcinoma (PROC) and in those with advanced or metastatic triple-negative breast cancer (TNBC), according to results from two industry-sponsored phase 2 trials.

Radical cystectomy cheaper than trimodal therapy in some bladder cancers

NEW YORK (Reuters Health) - 14/6/2019

In patients with localized muscle-invasive bladder cancer, radical cystectomy appears to have better outcome and may be much less costly than combining radiation, chemotherapy and endoscopic treatments, according to a retrospective study of Medicare data.

Adding radiation to chemo not better for locally-advanced endometrial cancer

(Reuters Health) - 12/6/2019

Supplementing chemotherapy with radiation failed to improve relapse-free survival in patients with stage III or IVA endometrial carcinoma, according to a comparison of the two therapies in 707 volunteers.

Checkpoint inhibitors may be retried after immune adverse event, with close monitoring

NEW YORK (Reuters Health) - 12/6/2019

After an immune-related adverse event, the risk-reward ratio for an anti-PD-1 (anti-programmed death-1) or anti-PD-L1 (anti-programmed death ligand-1) rechallenge seems to be acceptable if patients are closely monitored, researchers say.

Novel neoadjuvant approach may boost surgical success in pancreatic cancer

NEW YORK (Reuters Health) - 7/6/2019

In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.

Cardioprotective drugs can help avoid chemo disruption in some breast cancer patients

NEW YORK (Reuters Health) - 5/6/2019

ACE inhibitors or beta blockers can preserve cardiac function and avoid chemotherapy disruption in HER2-positive breast cancer patients treated with anthracyclines followed by trastuzumab, researchers say.

Venetoclax combination better than chlorambucil in CLL patients with coexisting conditions

(Reuters Health) - 4/6/2019

Among patients with chronic lymphocytic leukemia (CLL) and coexisting conditions such as heart, lung or digestive disease, adding venetoclax to obinutuzumab therapy produces longer progression-free survival than adding chlorambucil, newly-published results of the CLL14 trial have concluded.

Five-year study showed benefits of dabrafenib/trametinib therapy for metastatic melanoma

(Reuters Health) - 4/6/2019

Researchers combining the results of two large studies of volunteers with unresectable or metastatic melanoma have concluded that first-line therapy with dabrafenib combined with trametinib produces a 5-year benefit in about a third of patients with a BRAF V600E or V600K mutation.

Dual-drug induction therapy hikes survival in nasopharyngeal carcinoma

(Reuters Health) - 31/5/2019

In patients with locoregionally advanced nasopharyngeal carcinoma, adding gemcitabine and cisplatin induction to conventional treatment with platinum-based chemoradiotherapy increased the 3-year recurrence-free survival rate by 8.8 percentage points, according to results presented Friday at the American Society of Clinical Oncology's annual meeting in Chicago and online by the New England Journal of Medicine.

Adding daratumumab cuts progression/death rate in newly-diagnosed multiple myeloma

(Reuters Health) - 31/5/2019

More than two years after treatment, patients with newly-diagnosed multiple myeloma fare better with daratumumab added to the standard therapy of lenalidomide plus dexamethasone instead of standard therapy alone, according to published results from the MAIA study of 737 volunteers.

Apalutamide boosts progression-free survival by 52% in some prostate cancer patients

(Reuters Health) - 31/5/2019

In men with metastatic, castration-sensitive prostate cancer, adding apalutamide to conventional androgen-deprivation therapy (ADT) produced a 52% increase in the rate of radiographic progression-free survival, in a first interim analysis of the international TITAN study.

Drug combination may be effective against chronic lymphocytic leukemia

NEW YORK (Reuters Health) - 29/5/2019

Combining ibrutinib and venetoclax appears to produce complete remission or complete remission with incomplete normal-blood-count recovery in 88% of patients with chronic lymphocytic leukemia at one year, according to a new phase 2 study.

Guidelines not being followed for lymph node dissection in renal cancer

NEW YORK (Reuters Health) - 27/5/2019

Open radical nephrectomy for renal cell carcinoma (RCC) is associated with higher quality of lymph node dissection (LND), researchers report - but appropriate use of this approach is inconsistent.

Novartis' breast cancer treatment wins FDA approval

(Reuters) - 24/5/2019

The U.S. Food and Drug Administration (FDA) said on Friday that it had approved Novartis AG's treatment in combination with a hormone therapy for postmenopausal women, as well as for men, with a form of advanced breast cancer.

Colorectal cancer rates rising in younger adults

NEW YORK (Reuters Health) - 24/5/2019

The incidence of colorectal cancer (CRC) in adults under age 50 years appears to be rising in both Europe and the United States, according to two new reports.

Smoldering multiple myeloma less apt to progress with lenalidomide

NEW YORK (Reuters Health) - 23/5/2019

Lenalidomide cuts the risk that smoldering multiple myeloma, a precancerous condition, will progress to overt multiple myeloma in patients at moderate or high risk for progression, although side effects may be a limiting factor, according to results of a randomized controlled trial.

Dual-stain triage improves cervical cancer screening

NEW YORK (Reuters Health) - 16/5/2019

P16/Ki-67 dual-stain triage of women who test positive for human papillomavirus (HPV) in cervical cancer screening reduces referral to colposcopy without impairing detection of precancerous lesions, researchers report.

FDA okays Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia

ZURICH (Reuters) - 16/5/2019

Roche said on Thursday that the U.S. Food and Drug Administration had approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Only 13% of patients eligible for checkpoint inhibitors respond to them

NEW YORK (Reuters Health) - 13/5/2019

About 44% of cancer patients may be eligible for an FDA-approved checkpoint inhibitor drug, yet approximately 13% will respond to them, researchers say.

Nipple-sparing mastectomy safe for more women with breast cancer

NEW YORK (Reuters Health) - 9/5/2019

More women with breast cancer can benefit from less-invasive nipple-sparing mastectomy, according to an analysis of data from the Mayo Clinic presented at the American Society of Breast Surgeons (ASBrS) annual meeting.

Numerous new anticancer drugs not proven superior to standard of care

NEW YORK (Reuters Health) - 9/5/2019

Seventeen percent of randomized controlled trials that led to new anticancer drug approvals in the U.S. had suboptimal control arms and did not prove superiority to standard-of-care treatments, a quality-improvement study shows.

Bioimpedance spectroscopy helps prevent breast cancer-related lymphedema progression

NEW YORK (Reuters Health) - 8/5/2019

For triggering compression therapy to prevent progression of breast cancer-related lymphedema, bioimpedance spectroscopy (BIS) appears to be more effective than standard tape measure (TM) assessment of arm circumference, according to interim results of the PREVENT trial reported May 2 at the American Society of Breast Surgeons annual meeting.

Molecular profiling identifies potential treatment targets in many hard-to-treat pediatric cancers

NEW YORK (Reuters Health) - 7/5/2019

Molecular profiling enables the identification of potentially treatable alterations in many hard-to-treat childhood and adolescent cancers, according to results from the TRICEPS study.

Low-dose tamoxifen prevents recurrence of in situ breast cancer

NEW YORK (Reuters Health) - 3/5/2019

Tamoxifen at a low dose helps reduce local and contralateral recurrence of breast intraepithelial neoplasia, according to a new randomized controlled trial.

HER2 testing inaccessible for many women with breast cancer

NEW YORK (Reuters Health) - 2/5/2019

A survey of HER2 testing of breast cancer in 45 countries highlights major issues around access and affordability in low- and middle-income countries (LMIC), with some problems extending even to upper-middle-income countries (UMIC).

High-dose, single-fraction SBRT likely effective for non-spine bone metastases

NEW YORK (Reuters Health) - 2/5/2019

Single-fraction stereotactic body radiotherapy (SBRT) seems to be an effective option for patients with painful non-spine bone metastases and achieved higher pain response rates than standard multifraction radiotherapy (MFRT) in a phase 2 noninferiority study.

Adverse events common with PD-1 and PD-L1 inhibitors

NEW YORK (Reuters Health) - 1/5/2019

Most cancer patients treated with programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors experience at least one treatment-related adverse event, according to a new systematic review and meta-analysis.

Bb2121 CAR-T multiple myeloma treatment effective, but benefits may wane

NEW YORK (Reuters Health) - 1/5/2019

Doctors testing a chimeric antigen receptor T-cell (CAR-T) therapy against relapsed or refractory multiple myeloma say results from 33 patients show a complete response rate of 45%, although 40% of those patients with a complete response ultimately relapsed.

Sipuleucel-T could be more widely used for advanced prostate cancer

NEW YORK (Reuters Health) - 25/4/2019

More men with advanced prostate cancer could benefit from immunotherapy with sipuleucel-T, according to researchers who found use of the drug was influenced by income and other factors.

Basal cell carcinoma subtype reporting varies by practice, may put patients at risk

NEW YORK (Reuters Health) - 25/4/2019

Underreporting of basal cell carcinoma (BCC) subtypes occurs in academic, teaching and nonteaching institutions and may place patients at risk for inadequate or inappropriate therapy, researchers say.

Adverse skin effects tied to anti-PD1 response in melanoma

NEW YORK (Reuters Health) - 24/4/2019

Cutaneous toxic effects (CT) following treatment with anti-programmed-cell-death 1 (anti-PD-1) inhibitors may be encouraging news in patients with advanced melanoma, a retrospective review suggests.

Pesticide exposure linked to worse outcomes in diffuse large B-cell lymphoma

NEW YORK (Reuters Health) - 23/4/2019

Diffuse large B-cell lymphoma (DLBCL) patients exposed to pesticides on the job have worse overall survival (OS) and event-free survival (EFS) and are less likely to respond to treatment, according to new findings.

MRI identifies rectal cancer patients suitable for primary surgery

NEW YORK (Reuters Health) - 23/4/2019

MRI criteria can be used to identify "good prognosis" rectal-cancer patients for primary surgery (without chemoradiotherapy first), according to results from the QuickSilver clinical trial.

Many young cancer patients regret initial treatment decisions

(Reuters Health) - 23/4/2019

Most teens and young adults with cancer want a voice in how their tumors are treated, but almost one in four express regret about the initial treatment decisions made, a small study suggests.

Promising results in mice prompt human trial of novel lymphoma vaccine

NEW YORK (Reuters Health) - 23/4/2019

An in situ vaccine (ISV) combined with immune stimulants and radiotherapy showed efficacy in mice, prompting a phase 1 trial of patients with advanced indolent non-Hodgkin's lymphoma (INHL), researchers say.

Promising strategy identifies triple-negative breast cancers that might respond to tamoxifen

NEW YORK (Reuters Health) - 23/4/2019

Triple-negative breast cancer (TNBC) tumors with estrogen receptor-beta and a mutated p53 tumor suppressor might be responsive to tamoxifen, a series of preclinical studies suggests.

Lower risk of new primary cancer after carbon-ion radiotherapy of localized prostate cancer

NEW YORK (Reuters Health) - 12/4/2019

The risk of subsequent primary cancer is lower after carbon-ion radiotherapy than after photon radiotherapy for localized prostate cancer, researchers from Japan report.

Genetic testing under-utilized in ovarian cancer

NEW YORK (Reuters Health) - 12/4/2019

Only a minority of women with ovarian or breast cancer undergo recommended genetic testing, a new study suggests.

Surgery after systemic therapy tied to improved outcome of HER2+ advanced breast cancer

NEW YORK (Reuters Health) - 5/4/2019

Surgery is associated with higher survival rates in women with HER2-positive stage-4 breast cancer treated with systemic therapy, a retrospective study shows.

Lenalidomide plus rituximab ups response in relapsed indolent lymphoma

NEW YORK (Reuters Health) - 3/4/2019

In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.

Umbralisib shows promise in relapsed/refractory marginal zone lymphoma

NEW YORK (Reuters Health) - 3/4/2019

Umbralisib, an investigational oral inhibitor of PI3K-delta, has significant activity against relapsed/refractory marginal-zone lymphoma (MZL) and manageable side effects, according to early results from an ongoing phase 2b trial.

Gilteritinib improves survival in relapsed/refractory acute myeloid leukemia

NEW YORK (Reuters Health) - 2/4/2019

Treatment with the FLT3 inhibitor gilteritinib (Xospata) improves survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring an FLT3 mutation compared with standard salvage chemotherapy, according to final results of the phase 3 ADMIRAL clinical trial.

Aspirin use tied to reduced liver-cancer risk in chronic hepatitis B

NEW YORK (Reuters Health) - 28/3/2019

Daily aspirin therapy is associated with a lower risk of hepatocellular carcinoma (HCC) in hepatitis B patients, new findings show.

Fulvestrant-anastrozole combo improves survival in metastatic breast cancer

(Reuters Health) - 27/3/2019

More than six years after a study showed that women with hormone-receptor-positive metastatic breast cancer benefit from a combination of anastrozole and fulvestrant, extended results show the trend has become even more pronounced, but mostly for women not previously exposed to tamoxifen.

Fewer benign biopsies with digital breast tomosynthesis

NEW YORK (Reuters Health) - 26/3/2019

Digital breast tomosynthesis (DBT) substantially reduces the rate of benign biopsies without hampering cancer detection, according to results from the U.K. National Health Service Breast Screening Program.

Screening ultrasonography does not improve breast-cancer detection

NEW YORK (Reuters Health) - 21/3/2019

Rates of breast-cancer detection are similar after screening mammography with or without screening ultrasonography, according to an observational study.

Liquid biopsy spots early liver cancer in patients with HBV infection

NEW YORK (Reuters Health) - 20/3/2019

In high-risk patients with asymptomatic hepatitis B virus (HBV) infection, a liquid biopsy shows promise in detecting early-stage hepatocellular carcinoma (HCC), according to Chinese and U.S. researchers.

Brain surgery for metastasis tied to distinctive tumor spread

NEW YORK (Reuters Health) - 19/3/2019

In the absence of whole-brain radiation, neurosurgical resection in patients with brain metastases may boost pachymeningeal seeding, a new study hints.

Better lymphoma outcomes with bendamustine-rituximab combination

NEW YORK (Reuters Health) - 15/3/2019

The combination of bendamustine and rituximab provides better progression-free survival (PFS), event-free survival, and duration of response in patients with indolent non-Hodgkin lymphoma and mantle-cell lymphoma, compared with other regimens, according to five-year results from the BRIGHT follow-up study.

Breast cancer risk tied to DDT varies by exposure timing

(Reuters Health) - 14/3/2019

The once-common pesticide DDT has long been linked to an increased risk of breast cancer. Now, research suggests that women's age at first exposure to DDT may influence when in life the risk for breast malignancies is greatest.

Survival low in some after recurrence of cutaneous squamous-cell carcinoma

NEW YORK (Reuters Health) - 12/3/2019

Patients with cutaneous squamous-cell cancer of the head and neck who have disease recurrence after definitive treatment with surgery and postoperative radiotherapy have poor survival, according to a retrospective study.

Consensus guidelines target maintenance therapies for lymphomas after autologous transplant

NEW YORK (Reuters Health) - 7/3/2019

Maintenance therapy guidelines for lymphoma patients who have undergone autologous hematopoietic cell transplantation (HCT) were recently released by an expert panel from the American Society for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation.

Heart disease boosts risk for early death with abiraterone therapy for prostate cancer

NEW YORK (Reuters Health) - 6/3/2019

Men with advanced prostate cancer and cardiovascular disease (CVD) are at increased risk of dying during the first six months of treatment with abiraterone acetate (Zytiga) compared with their peers without pre-existing CVD, according to a retrospective study.

Liquid biopsy on par with tissue testing in advanced lung cancer

NEW YORK (Reuters Health) - 5/3/2019

In patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC), the Guardant360 liquid biopsy detects genomic biomarkers as well as standard-of-care tissue genotyping tests but with a faster turn-around time, new research suggests.

Heart-failure risk increased after adjuvant trastuzumab for breast cancer

NEW YORK (Reuters Health) - 28/2/2019

The long-term risk of heart failure nearly doubles after adjuvant chemotherapy with trastuzumab in breast cancer patients, according to a retrospective cohort study.

Study of AYA-cancer survivors can guide surveillance for new primary neoplasms

NEW YORK (Reuters Health) - 28/2/2019

A new study breaks down the excess risk of new primary malignancies in survivors of adolescent and young adult (AYA) cancers by the type of the first cancer, helping to inform surveillance efforts.

New tool predicts post-surgery problems in head and neck cancer

NEW YORK (Reuters Health) - 28/2/2019

A new preoperative risk index can help predict short-term adverse events (AEs) following surgery for head and neck cancer, according to Canadian researchers.

Advanced ovarian cancer survival not better with pelvic, paraaortic lymphadenectomy

(Reuters Health) - 27/2/2019

Women with advanced ovarian cancer and normal lymph nodes after complete resection experience no survival benefit from systematic pelvic and paraaortic lymphadenectomy, a randomized study of 647 volunteers has concluded.

Hypofractionated radiotherapy appropriate for low-risk prostate cancer

NEW YORK (Reuters Health) - 22/2/2019

Hypofractionated radiotherapy (HRT) should be a new practice standard for men with low-risk prostate cancer, based on a secondary analysis of a phase III trial.

Risk profile predicts survival in transplant-ineligible multiple myeloma

NEW YORK (Reuters Health) - 21/2/2019

In patients with multiple myeloma who are ineligible for stem-cell transplantation, the UK Myeloma Research Alliance Risk Profile (MRP) predicts overall survival across treatments and genetic factors, researchers say.

Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer

NEW YORK (Reuters Health) - 21/2/2019

Compared with standard radiotherapy, stereotactic ablative body radiotherapy (SABR) provides better local control and improved survival in patients with inoperable peripherally located stage 1 non-small-cell lung cancer (NSCLC), according to results of the CHISEL study.

Tisotumab vedotin shows some promise in early trial of solid tumors

NEW YORK (Reuters Health) - 19/2/2019

A new cancer drug has shown promise against multiple tumor types, in a first-in-human trial.

Expanding genetic testing for prostate cancer could improve patient management

NEW YORK (Reuters Health) - 15/2/2019

Expanding genetic testing beyond current guidelines could better stratify prostate cancer patients for the presence of pathogenic variants and improve their medical management, researchers say.

Neoadjuvant anti-PD-1 immunotherapy may improve glioblastoma outcomes

NEW YORK (Reuters Health) - 15/2/2019

Neoadjuvant immunotherapy with anti-PD-1 agents may improve outcomes in patients with resectable or recurrent glioblastoma, researchers report.

Novel radiation therapy promising for metastatic castration-resistant prostate cancer

NEW YORK (Reuters Health) - 14/2/2019

A novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA) has shown promising clinical activity in men with prostate-specific membrane antigen (PSMA)-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite multiple standard therapies.

Stereotactic body radiotherapy shows long-term safety in prostate cancer

NEW YORK (Reuters Health) - 14/2/2019

Stereotactic body radiotherapy (SBRT) appears to provide good long-term results and very few toxic effects in certain prostate cancers, according to data from thousands of patients.

Histological subtype best outcome predictor in orbital lymphoma

NEW YORK (Reuters Health) - 8/2/2019

How well orbital lymphoma (OL) patients do depends mainly on which of four subtypes they have, a new case series suggests.

Hyperthermic intraperitoneal chemo relatively safe for treating metastases

NEW YORK (Reuters Health) - 7/2/2019

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) appears to be at least as safe as other high-risk surgical oncology procedures, according to a retrospective study.

Focal cryotherapy shows encouraging prostate cancer control

NEW YORK (Reuters Health) - 31/1/2019

Focal cryotherapy for nonmetastatic clinically significant prostate cancer shows largely good outcomes at up to three years, according to UK researchers.

Hypothermic intraperitoneal chemo relatively safe for treating metastases

NEW YORK (Reuters Health) - 31/1/2019

Cytoreductive surgery with hypothermic intraperitoneal chemotherapy (CRS/HIPEC) appears to be at least as safe as other high-risk surgical oncology procedures, according to a retrospective study.

'Dense' breast rates steady with changing guidelines and technology

NEW YORK (Reuters Health) - 30/1/2019

The percentage of digital mammography screens assessed as dense has remained steady with changes in Breast Imaging Reporting and Data System (BI-RADS) guidelines and implementation of digital breast tomosynthesis, according to findings from the Breast Cancer Surveillance Consortium (BCSC).

Improved head and neck cancer survival with NSAIDs

NEW YORK (Reuters Health) - 29/1/2019

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with improved survival in patients with PIK3CA-altered head and neck cancer, researchers report.

Long-lasting menopause symptoms may be tied to slightly higher breast cancer risk

(Reuters Health) - 17/1/2019

Women who experience symptoms of menopause for many years may be slightly more likely to develop breast cancer than women who never had these symptoms, a U.S. study suggests.

Tumor markers limit imaging need in germ-cell tumor surveillance

NEW YORK (Reuters Health) - 16/1/2019

Tumor markers are a sensitive, radiation-sparing means of surveillance in children and adolescents with malignant germ-cell tumors, according to a retrospective review.

Life expectancy predicts benefit of immune-checkpoint inhibitors

NEW YORK (Reuters Health) - 15/1/2019

Late-life expectancy (LLE) is a better measure of survival benefit with immune-checkpoint inhibitors than is the American Society of Clinical Oncology Value Framework (ASCO-VF), according to a new report.

Task force adds aromatase inhibitors to advice on breast cancer chemoprevention in high-risk women

NEW YORK (Reuters Health) - 15/1/2019

In addition to tamoxifen and raloxifene, aromatase inhibitors (AIs) may now be considered for chemoprevention of breast cancer in women at high risk, the U.S. Preventive Services Task Force (USPSTF) said today in draft recommendations on the topic.

Respiratory medicine

Lung cancer radiotherapy tied to higher cardiac mortality

NEW YORK (Reuters Health) - 18/6/2019

In patients with locally advanced non-small-cell lung cancer undergoing radiotherapy, cardiac radiation exposure is an independent predictor of adverse outcomes, according to a retrospective analysis.

More than a third of people in the Americas may suffer from obstructive sleep apnea

NEW YORK (Reuters Health) - 14/6/2019

Obstructive sleep apnea (OSA) may affect as many as 37% of adults in the Americas, according to a review of epidemiological studies presented June 9 at Sleep 2019, the annual meeting of the Associated Professional Sleep Societies in San Antonio, Texas.

Enanta's lung infection therapy succeeds in mid-stage trial

(Reuters) - 14/6/2019

Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.

Early discharge, home treatment with rivaroxaban effective in low-risk pulmonary embolism

NEW YORK (Reuters Health) - 5/6/2019

Carefully selected patients with acute low-risk pulmonary embolism (PE) may be discharged early and treated at home safely and effectively with rivaroxaban, researchers say.

Broadening eligibility for lung cancer trials could have huge impact

NEW YORK (Reuters Health) - 5/6/2019

Adopting expanded inclusion criteria for clinical trials would nearly double the percentage of patients with advanced non-small-cell lung cancer (NSCLC) who are eligible to enroll, according to new research.

Stocking albuterol inhalers at schools could improve emergency asthma management

NEW YORK (Reuters Health) - 4/6/2019

Pediatricians should advocate for stocking albuterol inhalers at schools as a means of improving the management of asthma emergencies.

Atezolizumab added to chemo ups survival in lung cancer

NEW YORK (Reuters Health) - 31/5/2019

As first-line treatment for metastatic non-squamous non-small-cell lung cancer (NSCLC), the anti-PD-L1 agent atezolizumab (Tecentriq, Genentech) in combination with chemotherapy boosts survival compared with chemotherapy alone, according to a company-funded study.

Longer lung-cancer-screening intervals may sometimes be OK

NEW YORK (Reuters Health) - 27/5/2019

Lung-cancer-screening intervals longer than the current annual screening might be reasonable for some patients with neither emphysema nor consolidation on their lung CT, according to findings from the National Lung Screening Trial (NLST).

Nintedanib slows progression of systemic sclerosis-associated interstitial lung disease

NEW YORK (Reuters Health) - 24/5/2019

Nintedanib slows the decline of forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (ILD), according to findings from the SENSCIS trial.

Benralizumab does not reduce COPD exacerbations

NEW YORK (Reuters Health) - 24/5/2019

Benralizumab, which depletes eosinophils, does not reduce exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to results from two phase 3 trials.

Self-management app may improve outcomes in kids with persistent asthma

NEW YORK (Reuters Health) - 16/5/2019

AsthmaTracker, an electronic self-monitoring app for children with asthma, appears to increase participation in self-monitoring and improves asthma outcomes, according to a prospective study.

E-cigarettes and tobacco cigarettes induce similar acute respiratory response

NEW YORK (Reuters Health) - 15/5/2019

Short-term respiratory responses to use of e-cigarettes and tobacco cigarettes are similar, researchers say.

Vein-first ligation in lung-cancer surgery may increase survival

NEW YORK (Reuters Health) - 14/5/2019

Ligating effluent veins rather than arteries first during thoracoscopic lobectomy for non-small-cell lung cancer may reduce tumor-cell dissemination and hence increase survival, according to Chinese researchers.

New technique for minimally invasive lung cancer surgery promising

NEW YORK (Reuters Health) - 10/5/2019

A device that uses ultrasonic energy to seal pulmonary blood vessels during minimally invasive lung cancer surgery is a promising alternative to staplers and clips, researchers reported in a late-breaking clinical trial session May 4 at the American Association for Thoracic Surgery (AATS) annual meeting in Toronto.

Aclidinium bromide does not worsen cardiovascular outcomes in COPD

NEW YORK (Reuters Health) - 8/5/2019

The long-acting muscarinic antagonist (LAMA) aclidinium bromide reduces exacerbations of chronic obstructive pulmonary disease (COPD) without worsening cardiovascular outcomes in high-risk patients, according to results from the ASCENT-COPD randomized clinical trial.

Higher radiation doses tied to increased longevity in node-negative lung cancer

NEW YORK (Reuters Health) - 30/4/2019

Patients with node-negative stage-II non-small cell lung cancer (NSCLC) who receive higher radiation doses survive longer, researchers have found.

Deep-learning model may help predict NSCLC outcomes, survival

NEW YORK (Reuters Health) - 30/4/2019

A deep-learning model that uses serial imaging scans of tumors from patients with non-small-cell lung cancer (NSCLC) may predict treatment response and survival better than standard clinical parameters alone, researchers say.

Lung-cancer survival worse in patients with pulmonary fibrosis

NEW YORK (Reuters Health) - 25/4/2019

Non-small cell lung cancer (NSCLC) presents differently in patients with idiopathic pulmonary fibrosis (IPF), who also have higher overall and lung-cancer mortality, according to a new study.

Molecular classifier helps spot idiopathic pulmonary fibrosis

NEW YORK (Reuters Health) - 10/4/2019

A molecular classifier based on RNA-sequencing data from transbronchial lung biopsies can recognize an expression signature associated with usual interstitial pneumonia (UIP), the defining pathology of idiopathic pulmonary fibrosis (IPF).

Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC

NEW YORK (Reuters Health) - 2/4/2019

A novel liquid biopsy based on ultra-deep next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) can detect oncogenic drivers and resistance mutations in non-small-cell lung cancer (NSCLC), even when tissue biopsy fails to do so, researchers say.

Pembrolizumab may help some with advanced non-small-cell lung cancer

NEW YORK (Reuters Health) - 2/4/2019

Pembrolizumab (Keytruda, Merck) may have ongoing benefits for people with advanced non-small-cell lung cancer expressing programmed death ligand 1 (PD-L1), extended follow-up of an open-label study shows.

Algorithm automatically detects major thoracic diseases on chest x-rays

NEW YORK (Reuters Health) - 29/3/2019

A new deep-learning-based automated-detection (DLAD) algorithm accurately classifies major thoracic diseases on chest x-rays, researchers from South Korea report.

Cranial irradiation doesn't boost survival in locally advanced lung cancer

NEW YORK (Reuters Health) - 26/3/2019

Prophylactic cranial irradiation (PCI) doesn't appear to increase overall survival (OS) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC), long-term data from a phase 3 trial suggest.

Amphotericin B makes path for lung defense in cystic fibrosis

NEW YORK (Reuters Health) - 22/3/2019

Amphotericin B treatment may be able to restore the infection-fighting properties of the lungs in cystic fibrosis by standing in for a missing or deficient protein channel, studies in pigs and in human lung tissue suggest.

Lung-cancer screens effective in asbestos-exposed smokers

NEW YORK (Reuters Health) - 14/3/2019

Low-dose computed tomography (LDCT) screening can detect early lung cancers in smokers with a history of occupational asbestos exposure, new research shows.

Expansion sphincter pharyngoplasty may help some with sleep apnea

NEW YORK (Reuters Health) - 14/3/2019

Expansion sphincter pharyngoplasty could be a useful surgical option in certain patients with obstructive sleep apnea (OSA), a retrospective study from South Korea hints.

Poor asthma control linked with kids' school struggles

(Reuters Health) - 11/3/2019

Kids with asthma may struggle more in school when their symptoms aren't well-controlled, and minority students with this breathing disorder are more likely to fall behind than their white counterparts, a U.S. study suggests.

It's never too late to quit smoking before lung surgery

(Reuters Health) - 16/1/2019

Smokers preparing for lung cancer surgery should quit smoking before the operation, and the sooner the better, a new study shows.

Lung cancer screening complications may be higher than expected

(Reuters Health) - 14/1/2019

Invasive follow-up tests to examine abnormalities found with lung cancer screening may lead to more complications and extra healthcare costs than previously thought, a U.S. study suggests.

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

"The Medicom Conference Reports offer an excellent summary of the most important developments and presentations in medicine. They are well written and include the most recent references. Very informative and highly recommended."

Editor Medicom Conference Report series in Pulmonology

  • Prof dr P.N. Richard Dekhuijzen,
  • MD, PhD
  • Radboud university medical center
  • Dept. of Pulmonary Diseases

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.